Alpha-Hexachlorocyclohexane

Alpha-Hexachlorocyclohexane

SCHEMBL140813

Cl[C@H]1[C@H](Cl)[C@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

823298382338688239847Rdl1Rdl2Rdl3

The experimentally established mechanism targets of Alpha-Hexachlorocyclohexane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 1.00
CYP3A4 P08684 1/20 1.00
GABRA1 P14867 1/20 1.00
GABRB1 P18505 1/20 1.00
GABRG2 P18507 1/20 1.00
GABRR1 P24046 1/20 1.00
GABRB3 P28472 1/20 1.00
GABRA6 Q16445 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lindane SCHEMBL8575655 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
Lindane SCHEMBL10795898 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
Lindane SCHEMBL25895 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
Lindane SCHEMBL9120917 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
Lindane SCHEMBL75689 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
Lindane SCHEMBL472088 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
SCHEMBL8406626 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
Lindane SCHEMBL8110265 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
Lindane SCHEMBL9242537 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2
Lindane SCHEMBL140812 1.00 LMNA (1.00) LMNACYP3A4GABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346506-A1 Membrane-Mediated Electro-Oxidation-Reduction Deep Water Treatment Device and its Operation Method Thereof HARBIN INST TECHNOLOGY (CN) 2025-11-13 US claimed
WO-2024146144-A1 MEMBRANE-MEDIATED ELECTROOXIDATION-REDUCTION ADVANCED WATER TREATMENT DEVICE AND OPERATION METHOD THEREOF 哈尔滨工业大学 2024-07-11 WO claimed
CN-118139701-A Soil restoration device and method based on solar evaporation 徐浩兰 2024-06-04 CN claimed
CN-116282634-A Membrane-mediated conductive oxidation-reduction advanced water treatment device and operation method thereof 哈尔滨工业大学 2023-06-23 CN claimed
CN-115372493-A Method for detecting 24 pesticide residues in traditional Chinese medicine and application 广东微谱检测技术有限公司 2022-11-22 CN claimed
WO-2022217312-A1 APPARATUS AND PROCESS FOR SOLAR EVAPORATION-BASED SOIL REMEDIATION UNIVERSITY OF SOUTH AUSTRALIA (AU) 2022-10-20 WO claimed
CN-110988162-A Method for detecting pesticide residue in milk 李良浩 2020-04-10 CN claimed
US-20130105387-A1 TREATMENT FOR DEPOLLUTING WATER CONTAMINATED BY MICRO POLLUTANTS AND/OR EMERGENT POLLUTANTS, NOTABLY BY ORGANOCHLORINATED COMPOUNDS RHODIA OPERATIONS (FR) 2013-05-02 US claimed
US-4853223-A DIPPING USING AQUEOUS DISPERSION OF MICROENCAPSULATED PARASITICIDE CIBA-GEIGY CORPORATION (US) 1989-08-01 US claimed
US-20260021111-A1 GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS IMMEDICA PHARMA US INC (US) 2026-01-22 US disclosed
US-20250346506-A1 Membrane-Mediated Electro-Oxidation-Reduction Deep Water Treatment Device and its Operation Method Thereof HARBIN INST TECHNOLOGY (CN) 2025-11-13 US disclosed
US-12246026-B2 Ganaxolone for use in treatment of status epilepticus MARINUS PHARMACEUTICALS, INC. (US) 2025-03-11 US disclosed
WO-2024146144-A1 MEMBRANE-MEDIATED ELECTROOXIDATION-REDUCTION ADVANCED WATER TREATMENT DEVICE AND OPERATION METHOD THEREOF 哈尔滨工业大学 2024-07-11 WO disclosed
WO-2024141002-A1 NON-NUCLEIC ACID TARGET DETECTION METHOD BASED ON SPLIT CAS PROTEIN AND USE THEREOF 上海吐露港生物科技有限公司 2024-07-04 WO disclosed
US-4298615-A INSECTICIDES, MITICIDES BASF AKTIENGESELLSCHAFT (DE) 1981-11-03 US disclosed
US-4296108-A PESTICIDES BASF AKTIENGESELLSCHAFT (DE) 1981-10-20 US disclosed
US-4271171-A INSECTICIDES, MITICIDES BASF AKTIENGESELLSCHAFT (DE) 1981-06-02 US disclosed
US-4268506-A PESTICIDES BASF AKTIENGESELLSCHAFT (US) 1981-05-19 US disclosed
US-4240979-A Aroylureas BASF AKTIENGESELLSCHAFT (DE) 1980-12-23 US disclosed
US-3977952-A ULTRAVIOLET RADIATION, FORMING CARBON DIOXIDE C. F. SPIESS & SOHN (DT) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12246026-B2 Ganaxolone for use in treatment of status epilepticus CYP21A2, CYP17A1, HSD17B11 LMNA 3480/4885CYP3A4 65/4885GABRA1 183/4885
US-20260021111-A1 GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS CYP4A11, CYP21A2, CYP17A1 LMNA 2794/4885CYP3A4 18/4885GABRA1 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.